American Journal of Epidemiology Advance Access originally published online on October 26, 2005
American Journal of Epidemiology 2005 162(12):1153-1161; doi:10.1093/aje/kwi341
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Contribution |
Immune-Related Conditions and Immune-Modulating Medications as Risk Factors for Non-Hodgkin's Lymphoma: A Case-Control Study
1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Rockville, MD
2 Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN
3 Department of Preventative Medicine, Norris Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles, CA
4 Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA
5 Department of Family Medicine and Karmanos Cancer Institute, Wayne State University, Detroit, MI
Correspondence to Dr. Eric A. Engels, Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, DHHS, 6120 Executive Boulevard, EPS 8010, Rockville, MD 20852 (e-mail: engelse{at}exchange.nih.gov).
In immunosuppressed or autoimmune disease states, disordered immune responses may lead to non-Hodgkin's lymphoma (NHL). In a US population-based case-control study of NHL (1998–2000), the authors collected personal histories of immune-related conditions and use of immune-modulating therapies as well as family histories of autoimmune conditions. The study included 1,321 NHL cases and 1,057 controls; only half received some questionnaire components. NHL was associated with Sjögren's syndrome (odds ratio (OR) = 13, 95% confidence interval (CI): 1.7, 100) and lupus (OR = 4.2, 95% CI: 1.2, 15). Two specific NHL subtypes were strongly associated with Sjögren's syndrome: salivary gland (OR = 290, 95% CI: 33, 2600) and marginal zone (OR = 75, 95% CI: 9.1, 610). NHL was less convincingly associated with receipt of an organ transplant (OR = 2.0, 95% CI: 0.4, 11). Other autoimmune conditions were too rare to evaluate or not associated with NHL. Corticosteroid use was unrelated to NHL (OR = 1.0, 95% CI: 0.8, 1.2), but methotrexate use was marginally associated (OR = 2.3, 95% CI: 0.7, 7.5). Family history of dermatomyositis was associated with NHL (7 cases vs. 0 controls, OR = infinite; two-sided p = 0.02), but dermatomyositis was absent in cases themselves. Family history of remaining conditions was unrelated to NHL. Results suggest that disordered immunity in some immune-related conditions can lead to NHL.
autoimmune diseases; case-control studies; immunosuppression; lymphoma, non-Hodgkin; methotrexate; organ transplantation; risk factors; Sjogren's syndrome
Abbreviations: CI, confidence interval; NHL, non-Hodgkin's lymphoma; OR, odds ratio; SEER, Surveillance, Epidemiology, and End Results; SLE, systemic lupus erythematosus
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. E. Khan, V. Gallo, J. Linseisen, R. Kaaks, S. Rohrmann, O. Raaschou-Nielsen, A. Tjonneland, H. E. Johnsen, K. Overvad, M. M. Bergmann, et al. Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition Haematologica, June 1, 2008; 93(6): 842 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ekstrom Smedby, C. M. Vajdic, M. Falster, E. A. Engels, O. Martinez-Maza, J. Turner, H. Hjalgrim, P. Vineis, A. Seniori Costantini, P. M. Bracci, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium Blood, April 15, 2008; 111(8): 4029 - 4038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B Hanauer Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut, September 1, 2007; 56(9): 1181 - 1183. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Morton, J. J. Turner, J. R. Cerhan, M. S. Linet, P. A. Treseler, C. A. Clarke, A. Jack, W. Cozen, M. Maynadie, J. J. Spinelli, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood, July 15, 2007; 110(2): 695 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Wang, W. Cozen, J. R. Cerhan, J. S. Colt, L. M. Morton, E. A. Engels, S. Davis, R. K. Severson, N. Rothman, S. J. Chanock, et al. Immune Mechanisms in Non-Hodgkin Lymphoma: Joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Non-Hodgkin Lymphoma Risk Factors Cancer Res., May 15, 2007; 67(10): 5042 - 5054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bernatsky, J. L. Lee, and E. Rahme Non-Hodgkin's lymphoma--meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories Rheumatology, April 1, 2007; 46(4): 690 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Smedby, E. Baecklund, and J. Askling Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2069 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Landgren, E. A. Engels, R. M. Pfeiffer, G. Gridley, L. Mellemkjaer, J. H. Olsen, K. F. Kerstann, W. Wheeler, K. Hemminki, M. S. Linet, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst, September 20, 2006; 98(18): 1321 - 1330. [Abstract] [Full Text] [PDF]
|
|